Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B17 | O75795 | 2/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14884996 | 1.00 | UGT2B17 (0.41) | UGT2B17CXCR4CYP2D6P2RX7POLB | |
| SCHEMBL23937987 | 0.89 | DRD2 (0.36) | UGT2B17CXCR4P2RX7DRD2DRD1 | |
| SCHEMBL20851571 | 0.81 | CXCR4 (0.37) | CXCR4CYP2D6POLBDRD2DRD1 | |
| SCHEMBL12346329 | 0.81 | CXCR4 (0.37) | CXCR4CYP2D6POLBDRD2DRD1 | |
| SCHEMBL1688215 | 0.81 | CXCR4 (0.37) | CXCR4CYP2D6POLBDRD2DRD1 | |
| SCHEMBL11522496 | 0.79 | CXCR4 (0.36) | CXCR4CYP2D6 | |
| SCHEMBL11519118 | 0.79 | CXCR4 (0.36) | CXCR4CYP2D6 | |
| SCHEMBL20482614 | 0.79 | CXCR4 (0.39) | CXCR4CYP2D6ACHEFNTAFNTB | |
| SCHEMBL10287035 | 0.79 | POLB (0.36) | POLBACHEFNTAFNTB | |
| SCHEMBL6646898 | 0.79 | CXCR4 (0.36) | CXCR4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
| EP-0187977-B1 | TETRAHYDROQUINOLINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND ANTI-PEPTIC ULCER COMPOSITIONS CONTAING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-29 | — | — | EP | disclosed |
| US-4880815-A | GASTRIC JUICE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| US-4738970-A | Benzimidazolyl-thio-tetrahydroquinolines and anti-peptic ulcer compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-04-19 | — | — | US | disclosed |
| EP-0187977-A1 | Tetrahydroquinoline derivatives, process for preparing the same and anti-peptic ulcer compositions containg the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-07-23 | — | — | EP | disclosed |
| US-3991065-A | ANTIULCER AGENTS, CHEMICAL INTERMEDIATES | JOHN WYETH & BROTHER LIMITED (EN) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | UGT2B17 1446/4885CXCR4 2140/4885CYP2D6 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.